Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
Host: Craig M. McDonald, MD Guest: Crystal Proud, MD Guest: Aravindhan Veerapandiyan, MD There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoratio…
…
continue reading
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…
…
continue reading
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…
…
continue reading
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…
…
continue reading
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…
…
continue reading
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…
…
continue reading
Host: Daniel Gaudet, MD, PhD This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.…
…
continue reading
Host: Marc P. Bonaca, MD, MPH This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all…
…
continue reading
Host: Marc P. Bonaca, MD, MPH This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all…
…
continue reading
Host: Manesh R. Patel, MD This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.…
…
continue reading
Host: Manesh R. Patel, MD This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.…
…
continue reading
1
Not All Therapy Needs to Be Swallowed or Injected: The Future of Digital Therapeutics to Alleviate the Negative Symptoms of Schizophrenia
Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
1
Integration Is the Key to Success: How Will the New SCZ Therapies Fit Into Clinical Treatment Paradigms?
Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
1
Staying Current: What Do Recent Clinical Trial Data Say About the New and Emerging Treatment Options for CIAS?
Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
Host: Philip D. Harvey, PhD Guest: Martin Strassnig, MD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
1
Understanding CIAS: What Does Current Literature Say About the Etiology and Pathophysiology of CIAS?
Host: Martin Strassnig, MD Guest: Philip D. Harvey, PhD This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.…
…
continue reading
1
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
Host: Sara M. Tolaney, MD, MPH The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (e…
…
continue reading
Host: Jennifer I. Lim, MD, FARVO Guest: Carl Regillo, MD What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with …
…
continue reading
Guest: Vallerie V. McLaughlin, MD Host: Melisa A. Wilson, DNP, APRN, ACNP, BC Host: Sarah Kesler, MD Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from e…
…
continue reading
1
Overcoming Barriers to Timely Diagnosis and Classification of Interstitial Lung Disease: Considerations for Radiologists
Host: David Lynch, MB, BCh Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.
…
continue reading
Host: Pietro A. Canetta, MD Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.
…
continue reading
1
Leading the Charge on Obesity Management: The Endocrinologist’s Role in Empowering Community Providers to Join the Fight
Host: Daniel Bessesen, MD Guest: Joanna Miragaya Guest: Jaime Almandoz, MD, MBA, FTOS Gain experts’ insights and tools for endocrinology specialists to use to support and empower community-based colleagues in successful and sustainable obesity management practices.
…
continue reading
1
Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies
Host: Mario E. Lacouture, MD Host: Sapna Patel, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable mel…
…
continue reading
Host: Mario E. Lacouture, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…
…
continue reading
Host: Sapna Patel, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…
…
continue reading
1
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma
Host: Jeffrey S. Weber, MD, PhD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…
…
continue reading
Host: Sapna Patel, MD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…
…
continue reading
Host: Jeffrey S. Weber, MD, PhD This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.…
…
continue reading
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
Host: Robert Shin, MD, FANA, FAAN Guest: Enrique Alvarez, MD, PhD Guest: Jiwon Oh, MD, PhD, FRCPC The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, t…
…
continue reading
Host: Robert F. Kushner, MD Host: Donna Ryan, MD Host: Christopher D. Still, DO, FACN, FACP, FTOS Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting.
…
continue reading
Host: Jonathan Chung, MD Host: Seth Kligerman, MD Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.
…
continue reading
Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
…
continue reading
1
Multidisciplinary Approach to Diagnosing and Managing Indolent Systemic Mastocytosis: The Changing Landscape
Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape i…
…
continue reading
Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of …
…
continue reading
Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for ea…
…
continue reading
Guest: John Berk, MD Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flag…
…
continue reading
Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…
…
continue reading
Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and re…
…
continue reading